Compare CURV & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURV | SGHT |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 193.2M |
| IPO Year | 2021 | 2021 |
| Metric | CURV | SGHT |
|---|---|---|
| Price | $1.08 | $8.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $1.59 | ★ $6.66 |
| AVG Volume (30 Days) | ★ 435.5K | 207.6K |
| Earning Date | 12-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,039,486,000.00 | $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $2.03 |
| 52 Week High | $7.19 | $8.80 |
| Indicator | CURV | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 61.63 |
| Support Level | $0.94 | $8.00 |
| Resistance Level | $1.17 | $8.73 |
| Average True Range (ATR) | 0.10 | 0.44 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 23.09 | 56.25 |
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.